Drug Trial Radar · NCT04278417
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
689
Actual
Start
Nov 19, 2020
Primary completion
Oct 30, 2023
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.
Conditions
- Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mgBiological
3 x q6w loading injections, followed by q12w maintenance through Week 90
Panretinal photocoagulation laserProcedure
initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study EyeTime frame: Baseline, Week 54
Locations
120 sites in 16 countries. Site status is shown where the registry gives one.
Retina Associates SW
Tucson, Arizona
Retina- Vitreous Assoc Medical Group
Beverly Hills, California
Retina Consultants of Orange County
Fullerton, California
Salehi Retina Institute
Huntington Beach, California
Retina Consultants of Southern California
Redlands, California
Premiere Practice Management LLC
Torrance, California
Lundquist Inst BioMed at Harbor
Torrance, California
Miramar Eye Specialists
Ventura, California
Advanced Research LLC
Deerfield Beach, Florida
Rand Eye Institute
Deerfield Beach, Florida
Pinnacle Research Institute
Fort Lauderdale, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Florida Retina Institute
Jacksonville, Florida
Blue Oc Clin Res at Palm Bch Eye Ct
Lakeland, Florida
MedEye Associates
Miami, Florida
Florida Retina Institute
Orlando, Florida
Eye Center of North Florida
Panama City, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Associates
Elmhurst, Illinois
Midwest Eye Institute
Indianapolis, Indiana
John-Kenyon American Eye Institute PC
New Albany, Indiana
Retina Associates PA
Lenexa, Kansas
Cumberland Valley Retina Consultants
Hagerstown, Maryland
University of Mississippi Med Ctr
Jackson, Mississippi
Retina Associates Of Cleveland
Cleveland, Ohio
Dean McGee Eye Institute
Oklahoma City, Oklahoma
Cascade Medical Research Institute
Springfield, Oregon
Erie Retinal Surgery
Erie, Pennsylvania
Charleston Neuroscience Institute
Ladson, South Carolina
Southeastern Retina Associates P C
Knoxville, Tennessee
Austin Retina Associates
Austin, Texas
Texan Eye P A
Austin, Texas
Retina And Vitreous Of Texas
Bellaire, Texas
Retina Consultants TX Rsrch Ctr
Bellaire, Texas
Texas Retina Associates
Fort Worth, Texas
Valley Retina Institute PA
Harlingen, Texas
Retina Consultants of Houston PA
Houston, Texas
Medical Center Opthamology Assoc
San Antonio, Texas
Retina Associates Of South Texas PA
San Antonio, Texas
Virginia Eye Consultants
Norfolk, Virginia
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.